Precision Editing as a Therapeutic Approach for β-Hemoglobinopathies

Area of Science:

• Hematology
• Genetics
• Molecular Biology

Background:

• Beta-hemoglobinopathies are common genetic disorders with significant morbidity and mortality.
• Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is curative but limited by donor availability.
• Gene therapy and genome editing offer novel therapeutic strategies.

Purpose of the Study:

• To review the application of genome editing for treating beta-hemoglobinopathies.
• To highlight the potential of increasing fetal hemoglobin (HbF) expression.
• To discuss emerging targets and clinical translation of these approaches.

Main Methods:

• Utilizing genome editing tools (ZFN, TALENs, CRISPR/Cas9) to introduce mutations.
• Targeting HBG1/HBG2 promoters and BCL11A erythroid enhancer to increase HbF.
• Investigating novel HbF modulators like ZBTB7A, KLF-1, SOX6, and ZNF410.

Main Results:

• Genome editing successfully induced HPFH-like mutations, increasing HbF levels.
• Clinical trials demonstrate promising outcomes for sickle cell disease and thalassemia patients.
• Early results suggest transfusion independence and resolution of painful crises.

Conclusions:

• Genome editing represents a viable alternative curative strategy for beta-hemoglobinopathies.
• Targeting HbF reactivation via gene editing is advancing towards widespread clinical application.
• Long-term follow-up studies are crucial to confirm the sustained efficacy and safety of these treatments.